(Medage today) – Madrid – Veriniguat (Verquvo) missed the brand to reduce cardiac insufficiency (HF) hospitalizations but lowered the risk of cardiovascular death in patients with HF with a reduced ejection fraction (HFREF) but not recent decompensation …
